Suppr超能文献

华法林预防长期护理机构中伴有房颤的患者发生血栓:尽管考虑了卒中风险和出血风险,但低使用率仍持续存在。

Warfarin for prevention of thrombosis among long-term care residents with atrial fibrillation: evidence of continuing low use despite consideration of stroke and bleeding risk.

机构信息

Informagenics, LLC, Worthington, OH 43085, USA.

出版信息

Drugs Aging. 2013 Jun;30(6):417-28. doi: 10.1007/s40266-013-0067-y.

Abstract

OBJECTIVES

The aims of the study were to evaluate usage rates of warfarin in stroke prophylaxis and the association with assessed stages of stroke and bleeding risk in long-term care (LTC) residents with atrial fibrillation (AFib).

METHODS

A cross-sectional analysis of two LTC databases (the National Nursing Home Survey [NNHS] 2004 and an integrated LTC database: AnalytiCare) was conducted. The study involved LTC facilities across the USA (NNHS) and within 19 states (AnalytiCare). It included LTC residents diagnosed with AFib (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] diagnostic code 427.3X). Consensus guideline algorithms were used to classify residents by stroke risk categories: low (none or 1+ weak stroke risk factors), moderate (1 moderate), high (2+ moderate or 1+ high). Residents were also classified by number of risk factors for bleeding (0-1, 2, 3, 4+). Current use of warfarin was assessed. A logistic regression model predicted odds of warfarin use associated with the stroke and bleeding risk categories.

RESULTS

The NNHS and AnalytiCare databases had 1,454 and 3,757 residents with AFib, respectively. In all, 34 % and 45 % of residents with AFib in each respective database were receiving warfarin. Only 36 % and 45 % of high-stroke-risk residents were receiving warfarin, respectively. In the logistic regression model for the NNHS data, when compared with those residents having none or 1+ weak stroke risk and 0-1 bleeding risk factors, the odds of receiving warfarin increased with stroke risk (odds ratio [OR] = 1.93, p = 0.118 [1 moderate risk factor]; OR = 3.19, p = 0.005 [2+ moderate risk factors]; and OR = 8.18, p ≤ 0.001 [1+ high risk factors]) and decreased with bleeding risk (OR = 0.83, p = 0.366 [2 risk factors]; OR = 0.47, p ≤ 0.001 [3 risk factors]; OR = 0.17, p ≤ 0.001 [4+ risk factors]). A similar directional but more constrained trend was noted for the AnalytiCare data: only 3 and 4+ bleeding risk factors were significant.

CONCLUSIONS

The results from two LTC databases suggest that residents with AFib have a high risk of stroke. Warfarin use increased with greater stroke risk and declined with greater bleeding risk; however, only half of those classified as appropriate warfarin candidates were receiving guideline-recommended anticoagulant prophylaxis.

摘要

目的

本研究旨在评估华法林在预防中风中的使用情况,并探讨其与长期护理(LTC)机构中伴有心房颤动(AFib)的患者中风严重程度和出血风险评估等级之间的相关性。

方法

对两个 LTC 数据库(国家护理院调查[NNHS]2004 年和集成 LTC 数据库:AnalytiCare)进行了横断面分析。该研究涵盖了美国(NNHS)和 19 个州(AnalytiCare)的 LTC 机构。研究对象为诊断为 AFib 的 LTC 居民(国际疾病分类,第九版,临床修订版[ICD-9-CM]诊断代码 427.3X)。采用共识指南算法对中风风险类别进行分类:低危(无或 1 个以上弱中风危险因素)、中危(1 个中度)、高危(2 个中度或 1 个以上高危)。还根据出血风险因素的数量(0-1、2、3、4+)对居民进行分类。评估了华法林的当前使用情况。使用逻辑回归模型预测与中风和出血风险类别相关的华法林使用概率。

结果

NNHS 和 AnalytiCare 数据库分别有 1454 名和 3757 名患有 AFib 的居民。在每个数据库中,分别有 34%和 45%的 AFib 患者正在服用华法林。仅有 36%和 45%的高危中风患者正在服用华法林。在 NNHS 数据的逻辑回归模型中,与仅有 1 个或 1 个以上弱中风危险因素和 0-1 个出血危险因素的患者相比,随着中风风险的增加,服用华法林的概率也增加(比值比[OR]为 1.93,p = 0.118[1 个中度危险因素];OR = 3.19,p = 0.005[2 个中度危险因素];OR = 8.18,p ≤ 0.001[1 个以上高危因素]),而随着出血风险的增加则降低(OR = 0.83,p = 0.366[2 个危险因素];OR = 0.47,p ≤ 0.001[3 个危险因素];OR = 0.17,p ≤ 0.001[4 个以上危险因素])。AnalytiCare 数据中也观察到类似的方向但更受限制的趋势:只有 3 个和 4 个以上的出血危险因素具有显著意义。

结论

来自两个 LTC 数据库的结果表明,AFib 患者中风风险很高。华法林的使用随着中风风险的增加而增加,随着出血风险的增加而减少;然而,只有一半被归类为华法林合适候选者的患者正在接受指南推荐的抗凝预防治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c58/3663250/ea6f45119401/40266_2013_67_Fig1_HTML.jpg

相似文献

2
Usage of medications with high potential to interact with warfarin among atrial fibrillation residents in long-term care facilities.
Expert Opin Pharmacother. 2013 Feb;14(2):165-73. doi: 10.1517/14656566.2013.747509. Epub 2012 Nov 30.
3
Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting.
Arch Intern Med. 2001 Nov 12;161(20):2458-63. doi: 10.1001/archinte.161.20.2458.
4
Persistence of warfarin therapy for residents in long-term care who have atrial fibrillation.
Clin Ther. 2013 Nov;35(11):1794-804. doi: 10.1016/j.clinthera.2013.09.010. Epub 2013 Oct 15.
5
Warfarin use in nursing home residents: results from the 2004 national nursing home survey.
Am J Geriatr Pharmacother. 2012 Feb;10(1):25-36.e2. doi: 10.1016/j.amjopharm.2011.12.001. Epub 2012 Jan 9.
6
Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.
7
Use of warfarin therapy among residents who developed venous thromboembolism in the nursing home.
Am J Geriatr Pharmacother. 2012 Dec;10(6):361-72. doi: 10.1016/j.amjopharm.2012.11.003.
9
Geriatric Conditions Predict Discontinuation of Anticoagulation in Long-Term Care Residents With Atrial Fibrillation.
J Am Geriatr Soc. 2020 Apr;68(4):717-724. doi: 10.1111/jgs.16335. Epub 2020 Jan 22.
10
Use of warfarin in long-term care: a systematic review.
BMC Geriatr. 2012 Apr 5;12:14. doi: 10.1186/1471-2318-12-14.

引用本文的文献

1
Prescribing of anticoagulation for atrial fibrillation in primary care.
J Thromb Thrombolysis. 2022 Nov;54(4):616-624. doi: 10.1007/s11239-022-02655-z. Epub 2022 Apr 21.
3
The Utilization of Antithrombotic Therapy in Older Patients in Aged Care Facilities With Atrial Fibrillation.
Clin Appl Thromb Hemost. 2018 Apr;24(3):519-524. doi: 10.1177/1076029616686421. Epub 2017 Jan 10.

本文引用的文献

1
Use of warfarin in long-term care: a systematic review.
BMC Geriatr. 2012 Apr 5;12:14. doi: 10.1186/1471-2318-12-14.
3
Warfarin use in nursing home residents: results from the 2004 national nursing home survey.
Am J Geriatr Pharmacother. 2012 Feb;10(1):25-36.e2. doi: 10.1016/j.amjopharm.2011.12.001. Epub 2012 Jan 9.
5
Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
Am J Med. 2010 Jul;123(7):638-645.e4. doi: 10.1016/j.amjmed.2009.11.025.
7
Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis.
Eur Heart J. 2010 May;31(10):1257-65. doi: 10.1093/eurheartj/ehq021. Epub 2010 Feb 24.
8
Do current guidelines result in overuse of warfarin anticoagulation in patients with atrial fibrillation?
Ann Intern Med. 2009 Sep 1;151(5):355-6. doi: 10.7326/0003-4819-151-5-200909010-00012.
9
The net clinical benefit of warfarin anticoagulation in atrial fibrillation.
Ann Intern Med. 2009 Sep 1;151(5):297-305. doi: 10.7326/0003-4819-151-5-200909010-00003.
10
Advantages and disadvantages of using MDS data in nursing research.
J Gerontol Nurs. 2009 Jan;35(1):7-17. doi: 10.3928/00989134-20090101-09.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验